Interestingly, although it is generally accepted that ESR and CRP are performed similarly in observational studies [32], in the case of TFCN, we observed a trend for reciprocal changes involving downregulation of CRP and upregulation of ESR in subgroup 2 RA patients with a less prominent response to the drug. The gene discussed is CRP; the disease is rheumatoid arthritis.